Trials / Completed
CompletedNCT03934216
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified Dose on Specified Days |
| OTHER | Placebo | Specified Dose on Specified Days |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2021-06-13
- Completion
- 2023-04-04
- First posted
- 2019-05-01
- Last updated
- 2024-03-06
- Results posted
- 2022-07-06
Locations
107 sites across 13 countries: United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russia, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03934216. Inclusion in this directory is not an endorsement.